Fundraising Fox
/Companies
Sign in

Iktos

Paris, FR · 3 known investors

Find your way into Iktos

Sign up to see every warm intro you have to Iktos

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Iktos team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Spaya is an AI-powered retrosynthesis platform that identifies synthetic routes to target compounds by converting them into commercially available starting materials. It serves chemists and drug discovery teams seeking to accelerate research through rapid, customizable synthesis planning.

AI & Machine LearningBiotechDeep TechMedical Devices

Founders & leadership

Y
YannCo-founder and CEO
Q
QuentinCo-founder and CSO
N
NicolasCo-founder and CTO
YG
Yann Gaston-MatheFounder

Investors · 3

Omnes Capitallisted by Omnes CapitalParis

How we know: Omnes Capital's portfolio page · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

Debiopharm Innovation FundreportedLausanne · $1M – $5M

How we know: funding news · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 4

Altos LabsAltos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.
ACTOActo provides a mobile app platform for field-based sales teams in regulated industries to deliver training, coaching, and presentations with approved content and messaging. The solution includes keyword search, knowledge tracking via surveys, and push notification alerts for content updates.
PathosPathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.
MytosMytos builds robotic systems that automate the manufacturing of human cells, converting input stem cells into specific cell types such as neurons and heart cells over multiple weeks. It serves developers of regenerative medicines and cell therapies, aiming to scale production that is otherwise done by hand.

Companies working in the same space as Iktos.

In the news

Iktos raises € 15.5m Series A round to expand its artificial intelligence-based drug discovery technologies and solutionsprnewswire.com · Mar 2023

Frequently asked questions

What does Iktos do?
Spaya is an AI-powered retrosynthesis platform that identifies synthetic routes to target compounds by converting them into commercially available starting materials. It serves chemists and drug discovery teams seeking to accelerate research through rapid, customizable synthesis planning.
Who founded Iktos?
Iktos was founded by Yann, Quentin, Nicolas.
Who are Iktos's investors?
Iktos's investors include M Ventures, Omnes Capital, Debiopharm Innovation Fund.
Where is Iktos headquartered?
Iktos is headquartered in Paris, FR.